Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | PRKCA | P17252 | 5/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394036 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9010956 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL10620809 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL8467738 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL7416016 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL16726792 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL3763399 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9070261 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9787451 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL14952939 | 0.94 | PRKCA (0.67) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111265480-B | Epirubicin liposome and preparation method thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-4595681-A | Administering neutral glycerolipid | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1986-06-17 | — | — | US | disclosed |